The role of collagen type VI alpha 6 chain as a potential tumor suppressor in breast cancer: an immune regulation perspective

Abstract Background Collagen type VI alpha 6 chain (COL6A6), an essential component of epithelial cell basal lamina, is hypothesized to function as a tumor suppressor in various cancers, yet its role in breast cancer remains unclear. This study aimed to elucidate COL6A6 expression patterns, assess i...

Full description

Saved in:
Bibliographic Details
Main Authors: Jian-Di Li, Li-Li Deng, Jia-Yuan Luo, Chao-Hua Mo, Bang-Teng Chi, Wan-Ying Huang, Rong-Quan He, Di-Yuan Qin, Chang Song, Wen Zou, Gang Chen
Format: Article
Language:English
Published: BMC 2025-08-01
Series:BMC Cancer
Subjects:
Online Access:https://doi.org/10.1186/s12885-025-14680-1
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849226239219335168
author Jian-Di Li
Li-Li Deng
Jia-Yuan Luo
Chao-Hua Mo
Bang-Teng Chi
Wan-Ying Huang
Rong-Quan He
Di-Yuan Qin
Chang Song
Wen Zou
Gang Chen
author_facet Jian-Di Li
Li-Li Deng
Jia-Yuan Luo
Chao-Hua Mo
Bang-Teng Chi
Wan-Ying Huang
Rong-Quan He
Di-Yuan Qin
Chang Song
Wen Zou
Gang Chen
author_sort Jian-Di Li
collection DOAJ
description Abstract Background Collagen type VI alpha 6 chain (COL6A6), an essential component of epithelial cell basal lamina, is hypothesized to function as a tumor suppressor in various cancers, yet its role in breast cancer remains unclear. This study aimed to elucidate COL6A6 expression patterns, assess its impact on the tumor immune microenvironment, and uncover underlying molecular mechanisms in breast cancer progression. Methods Immunohistochemical staining of COL6A6 was conducted on 136 breast cancer tissues and 50 non-breast-cancer controls in-house. Global microarray and high-throughput sequencing datasets were analyzed to confirm mRNA expression trends, supported by single-cell RNA sequencing for expression intensity and distribution. Prognostic evaluation utilized a multicenter cohort of breast cancer patients through Kaplan–Meier survival and decision curve analyses. Tumor deconvolution and gene set enrichment analyses predicted COL6A6’s association with the tumor immune microenvironment and its molecular mechanisms. Mouse models, spatial transcriptomic sequencing, and transcriptional regulation analyses were employed to elucidate the intimate relationship between COL6A6 expression and immune cell distribution. Potential therapeutic agents for breast cancer patients were predicted by targeting the COL6A6 protein. Results COL6A6 protein staining intensity was significantly lower in breast cancer tissues compared to normal breast tissues (p < 0.0001). Integrated analysis confirmed COL6A6 downregulation in 4818 breast cancer tissues versus 1236 non-breast-cancer tissues (standardized mean difference =  − 1.27 [− 1.66, − 0.87]), supported by single-cell RNA sequencing. Reduced COL6A6 mRNA expression moderately discriminated breast cancer from non-breast-cancer tissues (pooled area under the curve = 0.88, sensitivity = 84.85%, specificity = 72.68%). Decreased COL6A6 expression correlated with poorer overall and relapse-free survival. It had a negative correlation with the purity of the tumor but a positive correlation with the quantity of stromal and immune cells in the tumor microenvironment. Immune regulatory pathways such as adaptive immune response, T cell differentiation, T cell proliferation, macrophage activation, and natural killer cell-mediated cytotoxicity were associated with the gene sets that were enriched in the analysis. Immune-related biological processes, such as immunoglobulin production, generation of immune response mediators, myeloid leukocyte activation, leukocyte chemotaxis, and neutrophil migration, were significantly enriched in mouse models immunized with a COL6A6 peptide vaccine. The downregulation of COL6A6 was associated with reduced immune cell infiltration in malignant regions of breast cancer tissue slices, which might be negatively regulated by the CBX2 transcription factor. MK-886 may serve as a promising therapeutic agent for breast cancer treatment by targeting COL6A6 (Vina score =  − 8.0). Conclusions COL6A6 may operate as a tumor suppressor in breast cancer, underscoring its correlation with immune activity in the tumor microenvironment. These findings suggest COL6A6 as a promising therapeutic target and prognostic biomarker warranting further investigation.
format Article
id doaj-art-cd31572adc404e779558227ce78f3637
institution Kabale University
issn 1471-2407
language English
publishDate 2025-08-01
publisher BMC
record_format Article
series BMC Cancer
spelling doaj-art-cd31572adc404e779558227ce78f36372025-08-24T11:34:39ZengBMCBMC Cancer1471-24072025-08-0125111610.1186/s12885-025-14680-1The role of collagen type VI alpha 6 chain as a potential tumor suppressor in breast cancer: an immune regulation perspectiveJian-Di Li0Li-Li Deng1Jia-Yuan Luo2Chao-Hua Mo3Bang-Teng Chi4Wan-Ying Huang5Rong-Quan He6Di-Yuan Qin7Chang Song8Wen Zou9Gang Chen10Department of Pathology, First Affiliated Hospital of Guangxi Medical UniversityDepartment of Clinical Oncology, First Affiliated Hospital of Guangxi Medical UniversityDepartment of Pathology, First Affiliated Hospital of Guangxi Medical UniversityDepartment of Pathology, Xiaolan People’s Hospital of ZhongshanDepartment of Pathology, First Affiliated Hospital of Guangxi Medical UniversityDepartment of Pathology, First Affiliated Hospital of Guangxi Medical UniversityDepartment of Clinical Oncology, First Affiliated Hospital of Guangxi Medical UniversityDepartment of Computer Science and Technology, School of Computer and Electronic Information, Guangxi UniversityDepartment of Pathology, First Affiliated Hospital of Guangxi Medical UniversityDepartment of Pathology, First Affiliated Hospital of Guangxi Medical UniversityDepartment of Pathology, First Affiliated Hospital of Guangxi Medical UniversityAbstract Background Collagen type VI alpha 6 chain (COL6A6), an essential component of epithelial cell basal lamina, is hypothesized to function as a tumor suppressor in various cancers, yet its role in breast cancer remains unclear. This study aimed to elucidate COL6A6 expression patterns, assess its impact on the tumor immune microenvironment, and uncover underlying molecular mechanisms in breast cancer progression. Methods Immunohistochemical staining of COL6A6 was conducted on 136 breast cancer tissues and 50 non-breast-cancer controls in-house. Global microarray and high-throughput sequencing datasets were analyzed to confirm mRNA expression trends, supported by single-cell RNA sequencing for expression intensity and distribution. Prognostic evaluation utilized a multicenter cohort of breast cancer patients through Kaplan–Meier survival and decision curve analyses. Tumor deconvolution and gene set enrichment analyses predicted COL6A6’s association with the tumor immune microenvironment and its molecular mechanisms. Mouse models, spatial transcriptomic sequencing, and transcriptional regulation analyses were employed to elucidate the intimate relationship between COL6A6 expression and immune cell distribution. Potential therapeutic agents for breast cancer patients were predicted by targeting the COL6A6 protein. Results COL6A6 protein staining intensity was significantly lower in breast cancer tissues compared to normal breast tissues (p < 0.0001). Integrated analysis confirmed COL6A6 downregulation in 4818 breast cancer tissues versus 1236 non-breast-cancer tissues (standardized mean difference =  − 1.27 [− 1.66, − 0.87]), supported by single-cell RNA sequencing. Reduced COL6A6 mRNA expression moderately discriminated breast cancer from non-breast-cancer tissues (pooled area under the curve = 0.88, sensitivity = 84.85%, specificity = 72.68%). Decreased COL6A6 expression correlated with poorer overall and relapse-free survival. It had a negative correlation with the purity of the tumor but a positive correlation with the quantity of stromal and immune cells in the tumor microenvironment. Immune regulatory pathways such as adaptive immune response, T cell differentiation, T cell proliferation, macrophage activation, and natural killer cell-mediated cytotoxicity were associated with the gene sets that were enriched in the analysis. Immune-related biological processes, such as immunoglobulin production, generation of immune response mediators, myeloid leukocyte activation, leukocyte chemotaxis, and neutrophil migration, were significantly enriched in mouse models immunized with a COL6A6 peptide vaccine. The downregulation of COL6A6 was associated with reduced immune cell infiltration in malignant regions of breast cancer tissue slices, which might be negatively regulated by the CBX2 transcription factor. MK-886 may serve as a promising therapeutic agent for breast cancer treatment by targeting COL6A6 (Vina score =  − 8.0). Conclusions COL6A6 may operate as a tumor suppressor in breast cancer, underscoring its correlation with immune activity in the tumor microenvironment. These findings suggest COL6A6 as a promising therapeutic target and prognostic biomarker warranting further investigation.https://doi.org/10.1186/s12885-025-14680-1Breast cancerCOL6A6Immunohistochemical stainingscRNA-seqTumor microenvironmentGSEA
spellingShingle Jian-Di Li
Li-Li Deng
Jia-Yuan Luo
Chao-Hua Mo
Bang-Teng Chi
Wan-Ying Huang
Rong-Quan He
Di-Yuan Qin
Chang Song
Wen Zou
Gang Chen
The role of collagen type VI alpha 6 chain as a potential tumor suppressor in breast cancer: an immune regulation perspective
BMC Cancer
Breast cancer
COL6A6
Immunohistochemical staining
scRNA-seq
Tumor microenvironment
GSEA
title The role of collagen type VI alpha 6 chain as a potential tumor suppressor in breast cancer: an immune regulation perspective
title_full The role of collagen type VI alpha 6 chain as a potential tumor suppressor in breast cancer: an immune regulation perspective
title_fullStr The role of collagen type VI alpha 6 chain as a potential tumor suppressor in breast cancer: an immune regulation perspective
title_full_unstemmed The role of collagen type VI alpha 6 chain as a potential tumor suppressor in breast cancer: an immune regulation perspective
title_short The role of collagen type VI alpha 6 chain as a potential tumor suppressor in breast cancer: an immune regulation perspective
title_sort role of collagen type vi alpha 6 chain as a potential tumor suppressor in breast cancer an immune regulation perspective
topic Breast cancer
COL6A6
Immunohistochemical staining
scRNA-seq
Tumor microenvironment
GSEA
url https://doi.org/10.1186/s12885-025-14680-1
work_keys_str_mv AT jiandili theroleofcollagentypevialpha6chainasapotentialtumorsuppressorinbreastcanceranimmuneregulationperspective
AT lilideng theroleofcollagentypevialpha6chainasapotentialtumorsuppressorinbreastcanceranimmuneregulationperspective
AT jiayuanluo theroleofcollagentypevialpha6chainasapotentialtumorsuppressorinbreastcanceranimmuneregulationperspective
AT chaohuamo theroleofcollagentypevialpha6chainasapotentialtumorsuppressorinbreastcanceranimmuneregulationperspective
AT bangtengchi theroleofcollagentypevialpha6chainasapotentialtumorsuppressorinbreastcanceranimmuneregulationperspective
AT wanyinghuang theroleofcollagentypevialpha6chainasapotentialtumorsuppressorinbreastcanceranimmuneregulationperspective
AT rongquanhe theroleofcollagentypevialpha6chainasapotentialtumorsuppressorinbreastcanceranimmuneregulationperspective
AT diyuanqin theroleofcollagentypevialpha6chainasapotentialtumorsuppressorinbreastcanceranimmuneregulationperspective
AT changsong theroleofcollagentypevialpha6chainasapotentialtumorsuppressorinbreastcanceranimmuneregulationperspective
AT wenzou theroleofcollagentypevialpha6chainasapotentialtumorsuppressorinbreastcanceranimmuneregulationperspective
AT gangchen theroleofcollagentypevialpha6chainasapotentialtumorsuppressorinbreastcanceranimmuneregulationperspective
AT jiandili roleofcollagentypevialpha6chainasapotentialtumorsuppressorinbreastcanceranimmuneregulationperspective
AT lilideng roleofcollagentypevialpha6chainasapotentialtumorsuppressorinbreastcanceranimmuneregulationperspective
AT jiayuanluo roleofcollagentypevialpha6chainasapotentialtumorsuppressorinbreastcanceranimmuneregulationperspective
AT chaohuamo roleofcollagentypevialpha6chainasapotentialtumorsuppressorinbreastcanceranimmuneregulationperspective
AT bangtengchi roleofcollagentypevialpha6chainasapotentialtumorsuppressorinbreastcanceranimmuneregulationperspective
AT wanyinghuang roleofcollagentypevialpha6chainasapotentialtumorsuppressorinbreastcanceranimmuneregulationperspective
AT rongquanhe roleofcollagentypevialpha6chainasapotentialtumorsuppressorinbreastcanceranimmuneregulationperspective
AT diyuanqin roleofcollagentypevialpha6chainasapotentialtumorsuppressorinbreastcanceranimmuneregulationperspective
AT changsong roleofcollagentypevialpha6chainasapotentialtumorsuppressorinbreastcanceranimmuneregulationperspective
AT wenzou roleofcollagentypevialpha6chainasapotentialtumorsuppressorinbreastcanceranimmuneregulationperspective
AT gangchen roleofcollagentypevialpha6chainasapotentialtumorsuppressorinbreastcanceranimmuneregulationperspective